autologous cell therapy

AIVITA Biomedical is a biotechnology company developing personalized vaccines for the prevention of infectious disease and treatment of cancer. Founded in 2016 by pioneers in the stem cell industry, it uses an autologous personal immunotherapy platform of dendritic cells loaded with tumor cells or multiple pathogen antigens. It also develops proprietary stem cell media and manufacturing methods, and a skin care product line.

clinical trialsdirected high-purity differentiationstem cell growthvaccine manufacturing

BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI) is a clinical-stage biotechnology company focused on developing autologous cellular therapeutics for neurodegenerative diseases. Its proprietary NurOwn platform uses autologous mesenchymal stem cells to produce neurotrophic factor-secreting (MSC-NTF) cells, manufactured individually from each patient's bone marrow and delivered intrathecally. The company also has an allogeneic exosome platform.

bone marrow harvesting and MSC isolationcell differentiationcryopreservationexosome platform developmentex-vivo cell expansionintrathecal administrationMSC-NTF cell production

Elixirgen Therapeutics develops life-changing therapies for rare diseases and aging-associated diseases using its ZSCAN4 and Bobcat® mRNA technologies. Its ZSCAN4 technology is in clinical trials to extend telomeres in patients with Telomere Biology Disorders, and its Bobcat® mRNA technology delivers large payloads such as full-length dystrophin for Duchenne muscular dystrophy.

clinical trialsmRNA designstem cell biology